Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.60 |
| ▸ | RELA | Q04206 | 1/20 | 0.60 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.58 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13676210 | 0.88 | TRPV1 (0.57) | MAPTNPC1RAB9AMCL1TRPV1 | |
| SCHEMBL13675960 | 0.85 | ALDH1A1 (0.75) | MAPTALDH1A1ALOX15MAPK1RAB9A | |
| SCHEMBL13676192 | 0.85 | TRPV1 (0.62) | MAPTRAB9ATRPV1NR1H4HDAC3 | |
| SCHEMBL13676000 | 0.85 | TRPV1 (0.62) | MAPTALDH1A1SMN1; SMN2TRPV1NR1H4 | |
| SCHEMBL13675963 | 0.85 | TRPV1 (0.62) | MAPTRAB9ATRPV1NR1H4HDAC3 | |
| SCHEMBL13676146 | 0.85 | TRPV1 (0.62) | MAPTALDH1A1NPC1RAB9ATRPV1 | |
| SCHEMBL13675964 | 0.85 | TRPV1 (0.62) | MAPTTRPV1NR1H4HDAC3HDAC4 | |
| SCHEMBL13676145 | 0.83 | TRPV1 (0.60) | TRPV1NR1H4HDAC3HDAC4HDAC1 | |
| SCHEMBL5286169 | 0.83 | TRPV1 (0.60) | MAPTRAB9ATRPV1NR1H4HDAC3 | |
| SCHEMBL20625313 | 0.83 | MAPT (0.71) | MAPTRAB9ATRPV1NR1H4HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264424-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264424-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. | 2009-10-22 | — | — | US | disclosed |
| US-7582657-B2 | Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582657-B2 | Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7579347-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579347-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264424-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | TRPV1, TRPV2, TRPV3 | MAPT 755/4885ALDH1A1 3238/4885ALOX15 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.